Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary) ; Lactulose
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Sponsors Bausch Health Companies
- 24 Jun 2023 Results presented at the European Association for the Study of the Liver Congress 2023
- 19 Jun 2023 According to Salix Pharmaceuticals Media release, data from this study will be at presented the European Association for the Study of the Liver (EASL) Congress 2023.
- 01 Sep 2020 Status changed from recruiting to completed.